us indic began strong note ahead today fed decis continu sideway depart crude report
show declin crude inventori major averag held level close broadli firmer fed hike feder fund rate
in-lin expect crude gold declin within telecom stock rule
vote reveal ownership tension reduc tp
reduc tp regardless whether vogtl proce three four co-own new nuclear project plant
vogtl vote proceed project time co-op oglethorp power ownership seek
negoti cost cap possibl concess vote postpon last night today
opinion latest tension rise cost increas risk georgia power project proceed lead
futur unexpect cost increas vcm report releas end august capit expenditur georgia
power ownership date account receipt toshiba guarante remain
capital-expenditure complet project figur increas august higher labor cost plu
anoth increas addit conting budget prior tp includ conserv valuat
assumpt writeoff vogtl increas higher uncertainti oglethorp
willing absorb cost increas also remain cogniz florida offtak jea aggress appeal co-
owner meag cancel project intensifi current vote delay oglethorp vote
requir proceed partnership agreement event cancel note georgia law requir
recoveri sunk expenditur georgia power howev would nevertheless keep writeoff assumpt
tp possibl risk head elect novemb
valuat reiter under-perform rate given sustain construct risk associ vogtl well
elect risk reduc tp account lower averag peer price-to-earnings well potenti addit
anoth posit step pipelin re-build syntimmun lead asset target neonat fc receptor fcrn
block igg recycl therefor lower circul igg level address sever indic
igg-medi similar soliri anoth pipeline-in-a-product molecul asset current
develop warm autoimmun hemolyt anemia waiha patient pemphigu vulgari pv pemphigu
foliaceu pf substanti option move indic deal strong strateg fit
current franchis state focu area deal term up-front mileston payment
upsid option new fcrn platform like reward investor fcrn class evolv
rapid pace physician gener see lot potenti igg-driven autoimmun diseas mechanist class
could efficaci sever autoimmun indic ivig/plasma exchange/rituximab util syntimmun list
igg-medi autoimmun diseas hematolog nephrolog dermatolog rheumatolog neurolog
earlier stage acquisit could contribut meaning pipelin rebuild like seen favor
fcrn class get competit first mover waiha sever compani develop fcrn antagonist argenx
ucb momenta affibodi immunov slight differ construct possibl
modif may translat clinic differenti earli declar winner point first-
mover waiha on-going phase studi data expect pivot studi follow
also disclos second indic move registr trial next year
analyst disclosur credit suiss seek busi compani cover research
report result investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest
stage set gmg result
ra announc posit zilucoplan result patient renal impair multi-cent open-label trial
enrol subject includ sever renal impair healthi control subject patient receiv
singl sc dose zilucoplan pk profil consist across group exposur similar
renal-impair patient healthi volunt advers event report result indic
zilucoplan dose renal impair patient need dose adjust allow rarx
potenti expand complement-medi renal disord ahu ln
gmg result remain investor focu compani patient dose august
primari efficaci endpoint chang qmg score baselin week top-line data expect late
see strong rational treatment gmg demonstr proof-of-act pnh
approach gmg clinic valid approv soliri
thought sofi latest securit
read-through salli overal sofi latest securit reaffirm view refi lender continu compet
aggress steadi drip rise rate slow refi volum pressur nim though think flat/declin
origin volum event remain competit question go forward
whether rise rate declin volum caus refi lender push harder in-school market well focu
refinanc undergrad-onli loan extent deposit fund bank citizen first republ high
qualiti low cost deposit fill void refi-lend pull back
yield see small uptick nim expect remain pressur yield vs
small uptick might suggest sofi increas price modestli aso size
smaller loan vs average securit
howev uncertain whether indic slow origin addit sofi nim declin
littl expect remain pressur rate rise
annual securit volum level sofi securit volum ytd compar
howev securit volum octob vs ytd suggest
rapid growth slow note account flow agreement privat securit
advanc rate still high sofi equiti rate advanc rate remain low advanc rate
vs advanc
resid refinanc prove popular loan resid medic dental program
compar think intellig decis underwrit
medical/dent resid could end make good long-term custom howev reidenc loan carri risk
resid yet secur job post-resid
undergrad-onli percentag remain high percentag undergraduate-onli loan pretti much level
slightli higher securit interest whether refi lender put
emphasi refinanc undergrad-onli loan nim compress refi product
headlin price previou day close unless otherwis note
compani mention price sep
receiv product pleas specifi credit suiss contact email call
analyst identifi report certifi respect compani secur individu analyz
view express report accur reflect person view subject compani secur
part compens directli indirectli relat specif recommend
view express report
analyst respons prepar research report receiv compens base upon variou factor includ
credit suiss total revenu portion gener credit suiss invest bank activ
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel
analyst coverag univers consist compani cover analyst within relev sector outperform
repres attract neutral less attract underperform least attract invest opportun
octob canadian well european rate base stock total return rel
analyst coverag univers consist compani cover analyst within relev sector outperform
repres attract neutral less attract underperform least attract invest opportun
latin american asia stock exclud japan australia rate base stock total return rel
averag total return relev countri region benchmark india bse sensex index prior octob
 canadian rate base stock absolut total return potenti current share price
rel attract stock total return potenti within analyst coverag univers australian new zealand
stock expect total return calcul includ roll dividend yield outperform rate assign
greater equal under-perform less equal neutral may
assign overlap rate rang allow analyst assign rate put
context associ risk prior may rang outperform under-perform rate
overlap neutral threshold oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type
commun includ invest recommend cours credit suiss engag invest
bank transact certain circumst
volatil indic stock defin volatil stock price move month
least past month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect
fundament and/or valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover
credit suiss distribut stock rate bank client
purpos nyse nasd rate distribut disclosur requir stock rate outperform neutral under-perform
